Results 181 to 190 of about 243,525 (310)
Association of MHC class II β domain polymorphism in channel catfish (Ictalurus punctatus) with natural infection by Ligictaluridus floridanus. [PDF]
Roldán GMG +5 more
europepmc +1 more source
Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes
This study identifies that pregnancy imprints a durable, pregnancy‐specific form of trained immune memory in uterine macrophages, marked by the emergence of LILRB3+/PIR‐B+ cells that expand across gestations, acquire a tolerogenic and metabolically rewired phenotype, and actively protect against inflammatory pregnancy loss in mice.
Jing Wang +8 more
wiley +1 more source
Case Report: A novel CIITA mutation causing MHC class II deficiency: first reported case in Morocco. [PDF]
Kattra AB +9 more
europepmc +1 more source
The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes. [PDF]
Gilles A +6 more
europepmc +1 more source
This study demonstrates significantly reduced Lkb1 expression in CD11c+ cells in chronic pancreatitis (CP) patients and animal models. Lkb1 deletion enhances CD11c+CD206+ macrophage infiltration and reprograms pancreatic stellate cells (PSCs) via OSM signaling.
Wenqing Zhang +10 more
wiley +1 more source
A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia. [PDF]
Golick L +7 more
europepmc +1 more source
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral +7 more
wiley +1 more source
Exploring MHC class II I-Ab blockade as a potential treatment for Sjögren's disease in the mouse model. [PDF]
Voigt A +7 more
europepmc +1 more source
Regulation of MHC Class II Gene Expression
Reith, Walter +4 more
openaire +3 more sources
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source

